A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Start Date18 Dec 2023

Sponsor / Collaborator

SciTech Development LLC

NCT06181760 / CompletedPhase 1

A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers

The goal of this clinical trial is to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions it aims to answer are: •How well is a single dose of fenretinide tolerated? AND •How is a single dose of fenretinide metabolized in healthy volunteers?
Participants will be asked to:
Remain confined in a clinical research unit for 5 days after dosing.
Provide blood samples for intense PK sampling and safety labs.
Fast for 10 hours prior to administration of study drug (fasted cohorts).
Consume a high fat meal prior to administration of study drug (fed cohort).
Return to the clinic for a single follow-up visit for safety assessments. Researchers will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.

Start Date22 Nov 2023

Sponsor / Collaborator

Island Pharmaceuticals Ltd.

NCT05999435 / Active, not recruitingPhase 2/3

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

Start Date20 Nov 2023

Sponsor / Collaborator

Laurent Pharmaceuticals, Inc.

100 Clinical Results associated with Fenretinide

100 Translational Medicine associated with Fenretinide

100 Patents (Medical) associated with Fenretinide

1,040

Literatures (Medical) associated with Fenretinide

01 Nov 2023·Cellular signalling

Fenretinide induces apoptosis and synergises the apoptosis inducing effect of gemcitabine through inhibition of key signalling molecules involved in A549 cell survival in in silico and in vitro analyses

Article

Author: Al-Bustany, Hazem A ; Muhammad, Hawzheen A ; Chawsheen, Mahmoud A ; Dash, Phil R

Fenretinide is a synthetic retinoid compound, which induces apoptosis via generating reactive oxygen species (ROS) and modulating PI3K/Akt/mTOR signalling pathway. We hypothesise that fenretinide's mechanism of action in triggering apoptosis may involve other targets, beside mTOR signalling pathway and it may augment apoptosis inducing effects of chemotherapeutic drugs in lung cancer. Time-lapse microscopy and Western blotting were used to evaluate apoptosis and apoptotic marker cleaved-Caspase 3 in A549 cells. Relative levels of protein phosphorylation and ROS were quantified by Human Phospho-Kinase Array Kit and CellROX® Green Reagent, respectively. Docking and simulation analyses of proteins and fenretinide interactions were identified and visualised by Discovery Studio Visualizer and AutoDock Vina software. Our results showed that fenretinide induced apoptosis in a dose dependant manner and combinations of fenretinide (5 μg/mL) and gemcitabine (1, 2, 4, 8 and 16 μg/mL) synergistically enhanced apoptosis in A549 cells. Fenretinide caused significant increase of cleaved-Caspase 3, de-phosphorylated p-S473 of Akt and failed to inhibit mTORC1 downstream targets. In silico results revealed that Akt required the lowest energy (-10.2 kcal/mol) to interact with fenretinide in comparison with other proteins. In conclusion, Akt may be exploited as a good target for induction of apoptosis in A549 cells and fenretinide has great potentials to fulfil this task. The mechanism by which fenretinide boosts the apoptosis inducing effects of gemcitabine, which is likely expected to be via inhibiting mTORC2 downstream targets. However, docking investigation revealed that fenretinide lacks specificity as it may also interact with several secondary targets beside Akt.

01 Oct 2023·Aquatic toxicology (Amsterdam, Netherlands)

Triphenyl phosphate-induced pericardial edema in zebrafish embryos is reversible following depuration in clean water

Article

Author: Ha, Megan ; Avila-Barnard, Sarah ; Zhang, Sharon ; Volz, David C ; Hoang, John ; Wiegand, Jenna ; Nemarugommula, Charvita ; Stapleton, Heather M

Triphenyl phosphate (TPHP) - a widely used organophosphate-based flame retardant - blocks cardiac looping during zebrafish development in a concentration-dependent manner, a phenotype that is dependent on disruption of embryonic osmoregulation and pericardial edema formation. However, it's currently unclear whether (1) TPHP-induced effects on osmoregulation are driven by direct TPHP-induced injury to the embryonic epidermis and (2) whether TPHP-induced pericardial edema is reversible or irreversible following cessation of exposure. Therefore, the objectives of this study were to determine whether TPHP-induced pericardial edema is reversible and whether TPHP causes injury to the embryonic epidermis by quantifying the number of DAPI-positive epidermal cells and analyzing the morphology of the yolk sac epithelium using scanning electron microscopy. First, we found that exposure to 5 μM TPHP from 24-72 h post-fertilization (hpf) did not increase prolactin - a hormone that regulates ions and water levels - in embryonic zebrafish, whereas high ionic strength exposure media was associated with elevated levels of prolactin. Second, we found that exposure to 5 μM TPHP from 24-72 hpf did not decrease DAPI-positive epidermal cells within the embryonic epithelium, and that co-exposure with 2.14 μM fenretinide - a synthetic retinoid that promotes epithelial wound repair - from 24-72 hpf did not mitigate the prevalence of TPHP-induced epidermal folds within the yolk sac epithelium when embryos were exposed within high ionic strength exposure media. Finally, we found that the pericardial area and body length of embryos exposed to 5 μM TPHP from 24-72 hpf were similar to vehicle-treated embryos at 120 hpf following transfer to clean water and depuration of TPHP from 72-120 hpf. Overall, our findings suggest that (1) the ionic strength of exposure media may influence the baseline physiology of zebrafish embryos; (2) TPHP does not cause direct injury to the embryonic epidermis; and (3) TPHP-induced effects on pericardial area and body length are reversible 48 h after transferring embryos to clean water.

11 Sep 2023·Angewandte Chemie (International ed. in English)

A Modular Approach for the Synthesis of Natural and Artificial Terpenoids

Article

Author: Ma, Shengming ; Wang, Weiyi ; Qian, Hui ; Huang, Dongyu ; Yu, Yibo

Abstract:

Many terpenoids with isoprene unit(s) demonstrating critical biological activities have been isolated and characterized. In this study, we have developed a robust chem‐stamp strategy for the construction of the key isoprene unit, which consists of two steps: one‐carbon extension of aldehydes to the alkenyl boronates by the boron‐Wittig reaction and the rhodium‐catalyzed reaction of alkenyl boronates with 2,3‐allenols to yield enals. This chem‐stamp could readily be applied repeatedly and separately, enabling the modular concise synthesis of many natural and pharmaceutically active terpenoids, including retinal, β‐carotene, vitamin A, tretinoin, fenretinide, acitretin, ALRT1550, nigerapyrone C, peretinoin, and lycopene. Owing to the diversified availability of the starting materials, aldehydes and 2,3‐allenols, creation of new non‐natural terpenoids has been realized from four dimensions: the number of isoprene units, the side chain, and the two terminal groups.

News (Medical) associated with Fenretinide

04 Jun 2024

·www.prnewswire.com

SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer

SciTech accelerates its mission to bring ST-001 to cancer patients. GROSSE POINTE FARMS, Mich., June 4, 2024 /PRNewswire/ -- SciTech Development, a clinical-stage, specialty oncology pharmaceutical company, today announced it has closed an additional $3.2 million in funding to continue the active enrollment and dosing of patients in its ongoing clinical trial for T-cell non-Hodgkin lymphoma (T-NHL). This new funding brings SciTech's total raised to over $12 million. SciTech's financing was led by Storm Lake Capital and Pointe Angels, alongside new and existing accredited investors. Proceeds from the financing will be used to advance the company's Phase 1b clinical trials of ST-001 for T-NHL and subsequent clinical trials for small cell lung cancer. "On behalf of Storm Lake Capital, we are thrilled with the initial clinical progress made by SciTech Development and pleased to further support the company through additional investment in its latest convertible note round." said Todd Carlson, Partner, Storm Lake Capital. "As early supporters, we have closely monitored SciTech's advancements, noting its adept handling of challenges and disciplined resource management. We value the management team's integrity and look forward to their continued success." SciTech's T-NHL trial began with the first patient dosed in late 2023 and is being conducted at six (6) prestigious cancer institutions located across the United States in PA, NY, TX, MI, and CA, with additional sites being added. Patient enrollment is now open. Trial information, including criteria and site locations, can be found at ClinicalTrials.gov with the identifier NCT04234048. SciTech anticipates starting a second Phase 1b small cell lung cancer (SCLC) trial to run concurrently with the T-cell lymphoma trial. "SciTech has achieved yet another milestone of having oversubscribed its second Convertible Note Round (CNR) of financing. This is a perfect reflection of the progress that has been made by our dedicated team. Our multicenter clinical trial is to reconfirm the safety and efficacy of the active drug, fenretinide, utilizing SciTech's novel nanoparticle delivery platform." said Earle Holsapple, CEO of SciTech. "We have opened a third CNR to continue advancing the Phase 1b studies for T-NHL and small cell lung cancer. In parallel, the company will launch a Series A capital raise to fund the completion of both trials and file for commercial approval with the FDA. We are confident that the drug's potential will soon be realized." ST-001 is SciTech's patented lead drug product, formulated with the active drug fenretinide (a synthetic retinoid derivative) plus specific phospholipids in a nanoparticalized delivery platform (SDP). ST-001 has achieved a breakthrough in solving the bioavailability issues of fenretinide without system-related toxicities, which allows the drug to reach and kill cancer cells. The FDA has granted ST-001 an Orphan Drug Designation, allowing 7 years of market exclusivity once approved. T-cell lymphoma, a rare disease, is being utilized as the initial gateway indication for ST-001 as the company plans to establish a foothold in other cancer indications. Previous studies with fenretinide have shown promise in at least 15+ other types of cancers, such as lung, breast, ovarian, cervical, pancreatic, leukemia, colo-rectal, head & neck, and brain cancers. These additional indications, plus the potential to add ST-001 as combination therapy, may add significant value to address the unmet clinical needs in oncology. About SciTech Development SciTech Development is a clinical-stage, specialty oncology pharmaceutical company that is revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer. With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented formulation that is currently in clinical trials for T-cell lymphomas (a form of non-Hodgkin lymphoma). ST-001 has been granted Orphan Drug Designation by the FDA, which allows 7 years of market exclusivity once approved. In addition, SciTech's nanoparticle drug delivery platform (SDP) maximizes the bioavailability of water-insoluble therapeutics and can potentially develop new drugs or improve other similarly challenged drugs. To learn more about SciTech, the science, and the team, please visit . Contact: SciTech Development: Investor Relations David Schaffer [email protected] Safe Harbor and Forward-Looking Statement: This document contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new products, services, or strategic opportunities, which may include a strategic transaction, plans regarding partnering activities, service pricing, or financial forecasts. Such statements are only predictions, and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any identified strategic transaction, the risk that products or services that appeared promising in early use do not demonstrate the same utility in larger-scale uses or trials, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on forward-looking contracts. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underly the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include but are not limited to, the effect of government regulation, political, environmental, competitive, and/or other material risks. SOURCE SciTech Development

Phase 1Orphan DrugIND

20 Dec 2023

·www.prnewswire.com

SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001

This study is designed to evaluate ST-001 for the treatment of T-cell non-Hodgkin's lymphoma (NHL). GROSSE POINTE, Mich., Dec. 20, 2023 /PRNewswire/ -- SciTech Development ("SciTech" or the "Company"), a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has dosed the first patient in its Phase 1 clinical trial with lead cancer drug candidate, ST-001 nanoFenretinide. ------------------------ Join us here to learn more about the Company and our science: ------------------------ "There have been relatively few new cancer breakthroughs for T-cell lymphoma in several years, so we are excited to announce this milestone for patients suffering from this rare disease." said Earle Holsapple, SciTech's President, and CEO. "Our scientific team has worked extremely hard to bring this new drug to the people that need it most. We currently have four active trial sites with world-renowned medical institutions in New York, California, Pennsylvania, and Michigan, with more sites coming onboard in early 2024 as the trials expand. SciTech is proud to be on the forefront of helping cancer patients and we thank everyone who has supported our journey." The active drug fenretinide has been clinically tested and deemed safe in over 3,000+ patients in previous clinical trials. However, due to bioavailability issues of past fenretinide formulations, high concentrations of the drug could not reach and kill the target cancer cells. SciTech led the effort to find the solution with its patented methods for phospholipids and nanoparticalization to enhance fenretinide's bioavailability, thus developing ST-001 nanoFenretinide. SciTech's Phase 1 clinical trials are targeting patients with T-cell non-Hodgkin's lymphoma, including Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome, and non-Cutaneous T-cell Lymphoma subtypes. The initial study will determine the Maximum Tolerated Dose (MTD) of ST-001 nanoFenretinide (IV infusion) in patients with CTCL and other T-cell non-Hodgkin's lymphoma. For more detailed trial information, please visit ClinicalTrials.gov; Identifier: NCT04234048. About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a broadly applicable anticancer drug. For more information about the Company, please visit: Contact Information: David Schaffer Director; Business Development and Investor Relations [email protected] Safe Harbor – Forward-Looking Statement: This document contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new products, services or strategic opportunities which may include a strategic transaction, plans regarding partnering activities, service pricing or financial forecasts. Such statements are only predictions, and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any identified strategic transaction, the risk that products or services that appeared promising in early use do not demonstrate the same utility in larger-scale uses or trials, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on forward-looking contracts. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underly the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, political, environmental, competitive, and/or other material risks. SOURCE SciTech Development

Phase 1

26 Oct 2023

·www.prnewswire.com

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies. The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community. Continue Reading SciTech Medical Advisory Board "SciTech is excited and incredibly proud that this world-class group of medical experts will assist us with innovative insights that enable us to bring ST-001 to patients who have limited options in their cancer treatments," said President and Managing Partner Earle Holsapple. "The clarity they bring in understanding the clinical needs of patients will serve to guide us through the commencement of our phase 1 clinical trial and through our subsequent expedited clinical program." The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D. Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity." Dr. Duvic is a Professor of Medicine and Dermatology practices in Houston, Texas, and holds the Blanche Bender Endowed Chair of Research. Her clinical research includes translational/molecular studies leading to improved therapies for cutaneous T-cell lymphomas. She has written over 500 peer-reviewed papers and a book on Retinoids. She participated in the development of topical and oral tazarotene and bexarotene which both received FDA approval. Larisa J. Geskin, MD, FAAD - "I am thrilled to support SciTech's innovative approach to cancer therapeutics. SciTech's patented nanoparticle platform, SDP, enhances the effectiveness and safety of fenretinide, which has shown promise in treating patients with incurable cutaneous lymphomas in preliminary studies. SciTech's flagship product, ST-001, stands out for its ability to deliver therapeutic doses without toxic side effects, greatly benefiting our patients." Dr. Geskin is a Professor of Dermatology (in Medicine, Division of Hematology-Oncology) at Columbia University Medical Center and the Director of the Comprehensive Cutaneous Oncology Center at the Columbia University Department of Dermatology. Dr. Geskin serves as the Immediate Past-President of the International Society for Cutaneous Lymphomas (ISCL), the Secretary-Treasurer of the US Cutaneous Lymphomas Consortium (USCLC), and the Founding Chair of the New York Cutaneous Lymphoma Consortium (NYCLC), among her many other responsibilities. Ajay K. Gopal, MD - "Based on the encouraging preclinical data from a variety of laboratories, our observed tolerability of fenretinide, and the unmet need in a spectrum of malignancies novel formulations such as ST-001 nanoFenretinide are certainly worthy of further investigation." Dr. Gopal received his undergraduate degree from Duke University and his MD from Emory University. He completed his internal medicine training at Duke University School of Medicine and his oncology training at the University of Washington and Fred Hutchinson Cancer Center, where he currently holds an endowed chair and serves as a Professor and Clinical Research Director for Hematologic Malignancies. Dr. Gopal has over 2 decades of experience in the development of novel therapies for lymphoma, as reflected by over 200 publications in the field, including the first translational and clinical trial data evaluating fenretinide in lymphoma. Contact: Earle Holsapple Email: [email protected] About SciTech Development SciTech Development, LLC is a clinical-stage pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines SDP and the drug fenretinide as a new drug product with potentially broad effectiveness in many cancers. For more information about the Company, please visit: SOURCE SciTech Development

Phase 1Executive Change

100 Deals associated with Fenretinide

External Link

KEGG	Wiki	ATC	Drug Bank
D04162	Fenretinide	-	DB05076

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	CA	Laurent Pharmaceuticals, Inc.	20 Nov 2023
COVID-19	Phase 3	US	Laurent Pharmaceuticals, Inc.	29 Jun 2020
Breast Cancer	Phase 3	IT	Istituto Europeo di Oncologia SRL	01 Dec 2009
Non-Muscle Invasive Bladder Neoplasms	Phase 3	US	National Cancer Institute	30 Jul 1998
Hormone receptor positive breast cancer	Phase 3	US	National Cancer Institute	01 Oct 1995
Carcinoma in situ of uterine cervix	Phase 3	US	National Cancer Institute	05 Mar 1993
Cervical Intraepithelial Neoplasia	Phase 3	US	National Cancer Institute	05 Mar 1993
Precancerous Conditions	Phase 3	US	National Cancer Institute	05 Mar 1993
Cystic Fibrosis	Phase 2	US	Laurent Pharmaceuticals, Inc.	10 Oct 2018
Cystic Fibrosis	Phase 2	AU	Laurent Pharmaceuticals, Inc.	10 Oct 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03265288 (APPLAUD, Biospace) Manual	Phase 2	Cystic Fibrosis	166	LAU-7b	jxfcwcypwa(vwxsvdqniy): difference = 1.23, P-Value = 0.0486	Positive	03 Nov 2022
				Placebo
NCT00546455 (CTgov)	Phase 2	Obesity \| Metabolic dysfunction-associated steatotic liver disease \| Insulin Resistance ... View more	21	Fenretinide (A- Fenretinide)	gnkbjchlor(mmjuldsrme) = esxpvwkvyc smmcsnlvaa (jbpzbqgcuv, kbjfjhdopu - wxkyvajuqq) View more	-	10 Feb 2021
				placebo (B-Placebo)	gnkbjchlor(mmjuldsrme) = ddgtzkxhdm smmcsnlvaa (jbpzbqgcuv, khbdrrnhii - ntcppskbel) View more
NCT00104923 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Hematologic Neoplasms	29	Fenretinide	qpgvsyvois(zrggemlabw) = bpzuivhkmh ankwjhgdes (mzswxjygkx )	Positive	15 Aug 2017
				Fenretinide (patients with response-evaluable peripheral T-cell lymphomas)	bfcjwaxcba(pwmsgrvwnp) = ipspxouovu kqodefnots (jkvwshmown ) View more
NCT00288067 (Pubmed \| Br J Haematol) Manual	Phase 1/2	Mantle-Cell Lymphoma \| B-Cell Lymphoma	32	fenretinide	kotrynahdn(hibhspxqqm) = No dose-limiting toxicities were observed. lkokrmqaqw (imedcblbtb ) View more	Positive	01 Feb 2017
				fenretinide+rituximab
NCT00080899 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Non-metastatic prostate cancer \| Adenocarcinoma of prostate	23	Fenretinide (N-(4-hydroxyphenyl) retinamide [4-HPR])	mtynggmpql(hhnjgqbgel) = hnhirbbdbx kpcdrfcshg (ryumxkovfi, jpmfczuybh - tzhuqalbbn) View more	-	06 Mar 2015
NCT00288067 (CTgov)	Phase 1/2	Recurrent Follicular Lymphoma \| Marginal zone lymphoma recurrent \| Acute Lymphoblastic Leukemia ... View more	32	Fenretinide+Rituximab (Fenretinide and Rituximab)	pyxwrqbhof(mwrnlelkka) = ccofgfwyfn iimfwclyxi (girtkmdufv, zfunogqwjc - klgnzcelzz) View more	-	06 Oct 2014
				Fenretinide+Rituximab (Fenretinide and Rituximab (Rituximab Naive))	hjshqaidhm(mnoeowegoh) = vdavkgflup srlrwqbdds (pzlkjxozmo, mfpdgnzuwy - owpyiitrur)
NCT00295919 (N2004-04, ASCO2014)	Phase 1	Neuroblastoma	80	4-HPR/LXS oral powder	vcubrqjyie(katiahwvib) = triskwvrbl bqgnyogqbs (wggkzyuogk, 1.35 - 36.9+) View more	-	20 May 2014
				Ketoconazole	pzhxqksbfs(mfqbokojgo) = nogbtknzbs oeeshfwgha (riokdbrcfx, 14.6, 22.1)
PhI-42 (ASCO2012)	Phase 1	Hematologic Neoplasms	25	Fenretinide (4-HPR) intravenous emulsion	zdstjwxsci(bubdqdlyku) = Reversible hypertriglyceridemia related to the intralipid vehicle accounted for 6/7 DLTs fkutgbwgai (jxqjmzqibl )	-	20 May 2012
AACR2012	Phase 1	Neuroblastoma recurrent	-	4-HPR/LXS	rcxjawbivj(egrhbbwesv) = stzhbeysyb pmxyyapsyn (jggrmkzcut )	-	15 Apr 2012
NCT00429936 (ARVO2011)	Phase 2	Geographic Atrophy serum retinol binding protein	-	Fenretinide	iqgtqxmkty(buphjbklls) = oljrrtgwxn hyxwhtjxhb (aebrfylrhl ) View more	-	01 Apr 2011
				Placebo	iqgtqxmkty(buphjbklls) = qssyatipgb hyxwhtjxhb (aebrfylrhl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis